Form 4 for MRNA Moderna
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-03 · accession 0001127602-25-007916 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-03-04 | 2025-03-03 | MRNA | Bancel Stephane | CEO, Dir | P - Purchase | $31.22 | +160.3K | 9.21M | +2% | +$5.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | P | A | 102,821 | $31.04 | 9,153,193 | I See Footnote | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $30.38 to $31.38. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. (F3) These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| 2 | Common | Common Stock | 2025-03-03 | P | A | 57,493 | $31.53 | 9,210,686 | I See Footnote | — | — | (F4) The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $31.39 to $31.96. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. (F3) These shares are owned directly by Boston Biotech Ventures. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |